12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
4 citations
,
May 2013 in “Canadian Urological Association Journal” Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
72 citations
,
October 1998 in “Baillière's clinical endocrinology and metabolism” Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
October 2015 in “Digital Library of Theses and Dissertations (Universidade de São Paulo)” Finasteride reduces prostate size and PSA levels in young men with hair loss.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.